Publications

Lu R* Ho W. Mitochondrial Dysfunction, Macrophage and Microglia in Brain Cancer. Frontiers in Cell and Developmental Biology 2020 In press.*Corresponding author.

Maggio D, Ho WS, Breese R, Walbridge S, Wang H, Heiss JD, Gilbert MR,Kovach JS, Lu R*, Zhuang Z. Inhibition of protein phosphatase-2A with PD-1 blockade enhances antitumor immunity and survival in glioblastoma.  Journal of Neuro-Oncology  2020 In press. *Corresponding author.

Bedognetti D, Ceccarelli M, Lu R*, …, the Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups. A comprehensive view on cancer immune responsiveness: A synopsis from the SITC workshop. J Immunother Cancer. 2019 *Co-first author.

Ho W, Wang H, Heiss J, Gilbert MR, Lu R*, Zhuang Z. Pharmacological inhibition of protein phosphatase-2A, with novel inhibitor LB-100, achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Nat Commun. 2018 May 29;9(1):2126. * Corresponding author.

Danaher P, Warren S, Lu R, Sullivan A, Samayoa J, Marincola F, Pekker I, Wallden B, Cesano A. Pan-cancer Adaptive Immune Resistance as Defined by The Tumor Inflammation (TIS): Results from The Cancer Genome Atlas (TCGA). J Immunother Cancer. 2018 Jun 22;6(1):63.

Turan T, Kannan D, Patel M, Barnes JM, Tanlimco S, Lu R, Halliwill K, Kongpachith S, Kline D, Hendrickx W, Cesano A, Butterfield LH, Kauffman H, Hudson T, Bedognetti D, Marincola F, Samayoa J. Immune Oncology, Immune Responsiveness and the Theory of Everything. J Immunother Cancer. 2018 Jun 5;6(1):50.

Ho W, Sizdahkhani S, Hao S, Song H , Seldomridge A, Tandle A, Maric D, Kramp T, Lu R , Heiss J, Camphausen K , Gilbert MR , Zhuang Z , Deric M. Park . LB-100, a novel Protein Phosphatase 2A Inhibitor (PP2A), Sensitizes Malignant Meningioma Cells to the Therapeutic Effects of Radiation. Cancer Lett. 2018 Feb 28;415:217-226.

Lu R*, Turan T, Samayoa J, Marincola FM. Cancer Immune Resistance: Can Theories Converge? Emerging Topics in Life Sciences. 2017 Dec 1(5):411. *Corresponding author.

Rutz S, Kayagaki N, Phung QT, Eidenschenk C, Noubade R, Lesch J, Lu R, Newton K, Huang OW,Cochran AG, DeVoss J, Webster J, Diehl L, Kirkpatrick DS, Lill JR, Ouyang W, Dixit VM. Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells. Nature. 2015 Feb 19;518(7539):417-21.

Noubade R, Wong K, Ota N, Rutz S, Eidenschenk C, Valdez PA, Ding J, Peng I, Sebrell A, Caplazi P, DeVoss J, Soriano RH, Sai T, Lu R, Modrusan Z, Hackney J, Ouyang W. NRROS negatively regulates the production of reactive oxygen species in phagocytes during host defense and autoimmunity. Nature. 2014 May 8;509(7499):235-9

Wu L, Li H, Luo X, Lu R, Ma Y, Wang R, Zhang, J, Yu H, Liu J. STAT3 activation in tumor cell-free lymph nodes predicts a poor prognosis for gastric cancer. Int J Clin Exp Pathol.2014 Feb 15;7(3)

Xin H, Lu R, Lee H, Zhang W, Zhang C, Deng J, Liu Y, Shen S, Wagner KU, Forman S, Jove R, Yu H. G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells.  J Biol Chem. 2013 May 10;288(19):13842-9.

Lu R, Pan H, Shively JE. CEACAM1 negatively regulates IL-1β production in LPS activated neutrophils by recruiting SHP-1 to a SYK-TLR4-CEACAM1 complex. PLoS Pathog. 2012;8(4).

Lu R, Kujawski M, Pan H, Shively JE. Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. Cancer Res. 2012 May 1;72(9):2239-50.

Lu R, Niesen MJ, Hu W, Vaidehi N, Shively JE. Lu R, Niesen MJ, Hu W, Vaidehi N, Shively JE. Interaction of actin with carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) receptor in liposomes is Ca2+ and phospholipid-dependent. J Biol Chem. 2011 Aug 5;286(31)